TABLE OF CONTENTS
1 INTRODUCTION 36
1.1 OBJECTIVES OF THE STUDY 36
1.2 MARKET DEFINITION 36
1.3 OVERVIEW OF THE EUROPE RADIOTHERAPY MARKET 36
1.4 CURRENCY AND PRICING 38
1.5 LIMITATIONS 38
1.6 MARKETS COVERED 38
2 MARKET SEGMENTATION 41
2.1 MARKETS COVERED 41
2.2 GEOGRAPHICAL SCOPE 42
2.3 YEARS CONSIDERED FOR THE STUDY 43
2.4 DBMR TRIPOD DATA VALIDATION MODEL 44
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 47
2.6 MULTIVARIATE MODELLING 48
2.7 PRODUCT AND SERVICES SEGMENT LIFELINE CURVE 49
2.8 MARKET END USERS COVERAGE GRID 50
2.9 DBMR MARKET POSITION GRID 51
2.10 VENDOR SHARE ANALYSIS 52
2.11 SECONDARY SOURCES 53
2.12 ASSUMPTIONS 53
3 EXECUTIVE SUMMARY 54
4 PREMIUM INSIGHTS 56
4.1 PESTLE ANALYSIS 57
4.2 PORTER'S FIVE FORCES MODEL 58
4.3 PRICING ANALYSIS 59
5 REGULATORY GUIDELINES FOR RADIOTHERAPY 61
6 MARKET OVERVIEW 64
6.1 DRIVERS 66
6.1.1 GROWING PREVALENCE OF CANCER DISEASE 66
6.1.2 NOVEL TECHNOLOGY IN RADIOTHERAPY FOR CANCER TREATMENT 66
6.1.3 INCREASING ADOPTION OF RADIOTHERAPY DEVICES AND PROCEDURES 67
6.1.4 RISING PREFERENCE FOR NON-SURGICAL PROCEDURES 67
6.2 RESTRAINTS 67
6.2.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 67
6.2.2 HIGH COST OF TREATMENT AND RADIOTHERAPY PROCEDURE 68
6.3 OPPORTUNITIES 68
6.3.1 INCREASING HEALTHCARE EXPENDITURE FOR CANCER TREATMENT 68
6.3.2 GROWING GOVERNMENT INITIATIVES TOWARD CANCER TREATMENT 69
6.3.3 RISING PATIENTS AWARENESS TOWARDS CANCER TREATMENT 70
6.4 CHALLENGES 70
6.4.1 STRICT REGULATIONS AND STANDARDS FOR APPROVAL AND COMMERCIALIZATION OF RADIOTHERAPY PRODUCTS 70
6.4.2 RISK OF RADIATION EXPOSURE 71
7 EUROPE RADIOTHERAPY MARKET, BY PRODUCT & SERVICES 72
7.1 OVERVIEW 73
7.2 SERVICES 75
7.3 PRODUCT 75
7.4 SOFTWARE 75
8 EUROPE RADIOTHERAPY MARKET, BY TYPE 76
8.1 OVERVIEW 77
8.2 EXTERNAL-BEAM RADIATION THERAPY 79
8.3 INTERNAL RADIATION THERAPY 79
8.4 SYSTEMIC RADIOTHERAPY/ RADIOPHARMACEUTICALS 79
8.5 OTHERS 79
9 EUROPE RADIOTHERAPY MARKET, BY APPLICATION 80
3.1 OVERVIEW 81
9.1 BREAST CANCER 84
9.2 LUNG CANCER 84
9.3 PROSTATE CANCER 84
9.4 COLORECTAL CANCER 84
9.5 LYMPHOMA 84
9.6 LIVER CANCER 84
9.7 THYROID CANCER 84
9.8 BRAIN CANCER 84
9.9 CERVICAL CANCER 85
9.10 SPINE CANCER 85
9.11 OTHERS 85
10 EUROPE RADIOTHERAPY MARKET, BY END USER 86
10.1 OVERVIEW 87
10.2 HOSPITALS 89
10.3 RADIATION THERAPY CENTERS 89
10.4 SPECIALTY CLINICS 89
10.5 OTHERS 89
11 EUROPE RADIOTHERAPY MARKET, BY DISTRIBUTION CHANNEL 90
11.1 OVERVIEW 91
11.2 DIRECT TENDERS 93
11.3 THIRD PARTY DISTRIBUTORS 93
11.4 OTHERS 93
12 EUROPE RADIOTHERAPY MARKET, BY REGION 94
12.1 EUROPE 95
13 EUROPE RADIOTHERAPY MARKET: COMPANY LANDSCAPE 157
13.1 COMPANY SHARE ANALYSIS: EUROPE 157
14 SWOT ANALYSIS 158
15 COMPANY PROFILE 159
15.1 SIEMENS HEALTHCARE GMBH 159
15.1.1 COMPANY SNAPSHOT 159
15.1.2 REVENUE ANALYSIS 159
15.1.3 COMPANY SHARE ANALYSIS 160
15.1.4 PRODUCT PORTFOLIO 160
15.1.5 RECENT DEVELOPMENT 160
15.2 ELEKTA 161
15.2.1 COMPANY SNAPSHOT 161
15.2.2 REVENUE ANALYSIS 161
15.2.3 COMPANY SHARE ANALYSIS 162
15.2.4 PRODUCT PORTFOLIO 162
15.2.5 RECENT DEVELOPMENTS 162
15.3 GENERAL ELECTRIC COMPANY 163
15.3.1 COMPANY SNAPSHOT 163
15.3.2 REVENUE ANALYSIS 163
15.3.3 COMPANY SHARE ANALYSIS 164
15.3.4 PRODUCT PORTFOLIO 164
15.3.5 RECENT DEVELOPMENT 164
15.4 HITACHI, LTD. 165
15.4.1 COMPANY SNAPSHOT 165
15.4.2 REVENUE ANALYSIS 165
15.4.3 PRODUCT PORTFOLIO 166
15.4.4 RECENT DEVELOPMENT 166
15.5 KONINKLIJKE PHILIPS N.V. 167
15.5.1 COMPANY SNAPSHOT 167
15.5.2 REVENUE ANALYSIS 167
15.5.3 COMPANY SHARE ANALYSIS 168
15.5.4 PRODUCT PORTFOLIO 168
15.5.5 RECENT DEVELOPMENT 168
15.6 ACCURACY INCORPORATED 169
15.6.1 COMPANY SNAPSHOT 169
15.6.2 REVENUE ANALYSIS 169
15.6.3 PRODUCT PORTFOLIO 170
15.6.4 RECENT DEVELOPMENT 170
15.7 BEBIG MEDICAL. 171
15.7.1 COMPANY SNAPSHOT 171
15.7.2 PRODUCT PORTFOLIO 171
15.7.3 RECENT DEVELOPMENT 171
15.8 BRAINLAB AG 172
15.8.1 COMPANY SNAPSHOT 172
15.8.2 PRODUCT PORTFOLIO 172
15.8.3 RECENT DEVELOPMENTS 172
15.9 CANON MEDICAL SYSTEMS CORPORATION 173
15.9.1 COMPANY SNAPSHOT 173
15.9.2 REVENUE ANALYSIS 173
15.9.3 PRODUCT PORTFOLIO 174
15.9.4 RECENT DEVELOPMENT 174
15.10 ECKERT & ZIEGLER BEBIG 175
15.10.1 COMPANY SNAPSHOT 175
15.10.2 REVENUE ANALYSIS 175
15.10.3 PRODUCT PORTFOLIO 176
15.10.4 RECENT DEVELOPMENT 176
15.11 IBA WORLDWIDE 177
15.11.1 COMPANY SNAPSHOT 177
15.11.2 REVENUE ANALYSIS 177
15.11.3 PRODUCT PORTFOLIO 178
15.11.4 RECENT DEVELOPMENT 178
15.12 LINATECH INC 179
15.12.1 COMPANY SNAPSHOT 179
15.12.2 PRODUCT PORTFOLIO 179
15.12.3 RECENT DEVELOPMENT 179
15.13 MEVION MEDICAL SYSTEMS 180
15.13.1 COMPANY SNAPSHOT 180
15.13.2 PRODUCT PORTFOLIO 180
15.13.3 RECENT DEVELOPMENT 180
15.14 NORDION (CANADA) INC. (A SUBSIDIARY OF SOTERA HEALTH) 181
15.14.1 COMPANY SNAPSHOT 181
15.14.2 PRODUCT PORTFOLIO 181
15.14.3 RECENT DEVELOPMENT 181
15.15 P-CURE 182
15.15.1 COMPANY SNAPSHOT 182
15.15.2 PRODUCT PORTFOLIO 182
15.15.3 RECENT DEVELOPMENT 182
15.16 SHINVA MEDICAL INSTRUMENT CO., LTD. 183
15.16.1 COMPANY SNAPSHOT 183
15.16.2 PRODUCT PORTFOLIO 183
15.16.3 RECENT DEVELOPMENT 183
15.17 UNITED IMAGING HEALTHCARE CO., LTD 184
15.17.1 COMPANY SNAPSHOT 184
15.17.2 PRODUCT PORTFOLIO 184
15.17.3 RECENT DEVELOPMENT 184
15.18 VIEWRAY TECHNOLOGIES, INC. (VIEWRAY) 185
15.18.1 COMPANY SNAPSHOT 185
15.18.2 REVENUE ANALYSIS 185
15.18.3 PRODUCT PORTFOLIO 186
15.18.4 RECENT DEVELOPMENT 186
15.19 ZEISS INTERNATIONAL 187
15.19.1 COMPANY SNAPSHOT 187
15.19.2 REVENUE ANALYSIS 187
15.19.3 COMPANY SHARE ANALYSIS 188
15.19.4 PRODUCT PORTFOLIO 188
15.19.5 RECENT DEVELOPMENT 188
16 QUESTIONNAIRE 189
17 RELATED REPORTS 193

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.